Compare EVTL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | IMUX |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | 66 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.7M | 75.2M |
| IPO Year | N/A | 2013 |
| Metric | EVTL | IMUX |
|---|---|---|
| Price | $3.73 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $13.20 | $4.25 |
| AVG Volume (30 Days) | 714.1K | ★ 3.2M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $0.51 |
| 52 Week High | $7.60 | $1.51 |
| Indicator | EVTL | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 32.65 | 58.29 |
| Support Level | $3.71 | $0.64 |
| Resistance Level | $4.70 | N/A |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 2.96 | 51.49 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.